Researchers have created a personal epidemic.

Published Date: 08 Mar 2023

A group of scientists led by Dr. Yamin Zhang and Dr. Colin Franz of Shirley Ryan AbilityLab and Dr. John Rogers of Northwestern University have developed a new technique. Change...

Read Full News

Todays Updates


Residual Asthma Exacerbations on Biologics Vary by Mechanism


Residual Asthma Exacerbations on Biologics Vary by Mechanism

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio


Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH


Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS


Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH


Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH


A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis


ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

Todays Updates


Residual Asthma Exacerbations on Biologics Vary by Mechanism


Residual Asthma Exacerbations on Biologics Vary by Mechanism

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio


Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH


Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS


Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH


Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH


A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis


ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

2.

Dense breasts: What it means and what women can do about screening

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

What Do Patients Want Doctors to Know About Breast Cancer Recurrence?

5.

Radiotherapy of cancer: Researchers enable better cancer treatment using existing medical equipment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot